Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 8/20 | 0.48 |
| ▸ | TLR1 | Q15399 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617550 | 0.83 | ALDH1A1 (0.47) | TLR2TLR1ALDH1A1 | |
| SCHEMBL1616767 | 0.82 | ALDH1A1 (0.49) | TLR2TLR1ALDH1A1MAPK1 | |
| SCHEMBL16914028 | 0.81 | TLR2 (0.48) | TLR2TLR1ALDH1A1 | |
| SCHEMBL8475128 | 0.81 | ALDH1A1 (0.50) | TLR2TLR1ALDH1A1MAPK1 | |
| SCHEMBL23292585 | 0.80 | TLR2 (0.49) | TLR2TLR1ALDH1A1 | |
| SCHEMBL1616714 | 0.80 | ALDH1A1 (0.47) | TLR2TLR1ALDH1A1MAPK1 | |
| SCHEMBL8034073 | 0.80 | TLR2 (0.49) | TLR2TLR1ALDH1A1MAPK1 | |
| SCHEMBL16914219 | 0.80 | TLR2 (0.44) | TLR2TLR1ALDH1A1MAPK1 | |
| SCHEMBL16255769 | 0.79 | NR2E1 (0.44) | PDE3BNR2E1 | |
| SCHEMBL10153120 | 0.78 | ALDH1A1 (0.49) | TLR2TLR1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186247-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3186247-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-106795152-B | Protein kinase inhibitors | 安斯达尔生物技术有限责任公司 | 2020-01-31 | — | — | CN | disclosed |
| EP-2880038-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2880038-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3186247-A1 | PROTEIN KINASE INHIBITORS | Astar Biotech LLC (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016029776-A1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016029776-A1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2016-03-03 | — | — | WO | disclosed |
| US-9174996-B2 | Protein kinase inhibitors | ASTAR BIOTECH LLC (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174996-B2 | Protein kinase inhibitors | ASTAR BIOTECH LLC (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140364436-A1 | Protein Kinase Inhibitors | ASTAR BIOTECH LLC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364436-A1 | Protein Kinase Inhibitors | ASTAR BIOTECH LLC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8859553-B2 | Protein kinase inhibitors | ASTAR BIOTECH LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859553-B2 | Protein kinase inhibitors | ASTAR BIOTECH LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859553-B2 | Protein kinase inhibitors | ASTAR BIOTECH LLC (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2014019338-A1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014019338-A1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20140031354-A1 | Protein Kinase Inhibitors | ASTAR BIOTECH LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031354-A1 | Protein Kinase Inhibitors | ASTAR BIOTECH LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031354-A1 | Protein Kinase Inhibitors | ASTAR BIOTECH LLC (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364436-A1 | Protein Kinase Inhibitors | MAP3K9, MAP3K6, MAP3K8 | TLR2 2979/4885TLR1 3820/4885ALDH1A1 4389/4885 |
| US-20140031354-A1 | Protein Kinase Inhibitors | MAP3K1, MAP3K5, MAP3K7 | TLR2 2834/4885TLR1 2793/4885ALDH1A1 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.